Imaging of Ultra-Weak Photon Emission in a Rheumatoid Arthritis Mouse Model by Wijk, E.P.A. van et al.
Imaging of Ultra-Weak Photon Emission in a Rheumatoid
Arthritis Mouse Model
Eduard van Wijk1,3,5,6*, Masaki Kobayashi2, Roeland van Wijk1,5, Jan van der Greef1,3,4
1 Sino-Dutch Centre for Preventive and Personalized Medicine/Centre for Photonics of Living Systems, Leiden University, Leiden, The Netherlands, 2 Department of
Electronics and Intelligent Systems, Tohoku Institute of Technology, Sendai, Japan, 3 Division of Analytical Biosciences, Netherlands Metabolomics Centre, LACDR, Leiden
University, The Netherlands, 4 TNO Netherlands Organization for Applied Scientific Research, Zeist, The Netherlands, 5 Meluna Research, Geldermalsen, The Netherlands,
6 Samueli Institute, Alexandria, Virginia, United States of America
Abstract
Ultra-weak photon emission (UPE) of a living system received scientific attention because of its potential for monitoring
increased levels of reactive oxygen species (ROS) in the pathogenesis of rheumatoid arthritis (RA). In this study, a highly
sensitive cryogenic charge-coupled device (CCD) camera was used to monitor in a RA mouse model the photon emission
both without and with luminol. For that purpose, arthritis was induced in mice utilizing a repeated co-administration of type
II collagen with lipopolysaccharide. Quantitative imaging of ultra-weak photon emission of the front and back paws of the
animals was initiated 70 days after the first injection. All of the animals were measured once without luminol and once again
immediately after luminol injection. Data illustrated a higher UPE intensity after initiating arthritis by CII-injection of the
animals. The increase in UPE intensity was measured with and without using luminol indicating that this imaging
technology may be useful for the future study of human RA.
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Introduction
Convincing evidence supports a role for oxidative stress and the
subsequent production of reactive oxygen species (ROS) in the
pathogenesis of many chronic diseases. The importance of ROS
has stimulated the development of techniques for their estimation
and evaluation of therapeutic interventions. In particular, the
techniques that can be applied both non-invasively and locally
estimating radiation energy vis-à-vis documentation of photon
emission in the UV, visible and near IR ranges. Since the 1980’s,
many experiments have revealed that weak photon emission could
originate from natural biological reactions of free radicals and
their derivatives, and also from simple cessation of electronically
excited states. As examples may be listed the mitochondrial
respiration chain, lipid peroxidation, peroxisomal reactions,
oxidation of tyrosine and tryptophan residues in proteins, etc.
[1–6]. One of the major sources of weak biological photon
emission is mitochondrial oxidative metabolism and lipid perox-
idation. It is due to the excited electrons of singlet oxygen 1O2 and
carbonyl species R = O*. When an excited carbonyl or singlet
oxygen is released to the ground state, it can emit its energy as a
photon in the visible range. Photon emission from dimole emission
of singlet oxygen (1O2+1O2 R 2 3O2+ hn) and carbonyl species
(R = O* R R = O+hn) range in the order of 634–703 nm and
450–550 nm, respectively. The origin of weak radiation was also
frequently discussed from the point of view that, usually, only
primary emission emanating from the surface would be measured.
Emission occurring in deeper layers may be absorbed and become
part of the transmission of excited states, both dark and light, the
latter resulting in secondary radiation from other sources [7,8].
Early studies have already indicated that this technique (utilizing
photomultipliers and photon emission imaging equipment) could
serve as a useful biological marker in order to detect physiological
malfunctions in tumor development. In cell studies, experimental
data pointed to higher primary and secondary emissions of tumor
cells compared to normal parental cells [9–13]. The data have
been confirmed utilizing normal and tumor tissue [14]. The use of
two-dimensional imaging plus photon counting of ultra-weak
photon emission (UPE) from a transplanted bladder cancer into
the feet of nude mice was reported in 1995 [15]. During the early
log phase of cancer cell growth (prior to necrosis, hemorrhage, and
leukocyte infiltration) increased photon emission was observed in
the implanted tumor region indicating emission from the actively
proliferating cancer. Other data confirmed the increased photon
emission of tumors [16]. Utilizing a highly sensitive, ultra-low-
noise charge-coupled device (CCD) camera system, these authors
also recorded UPE from mice at the site that ovarian cancer cells
were transplanted.
Increased oxidative stress also plays a significant role in the
pathogenesis of Rheumatoid Arthritis (RA) [17–20]. The same
biological marker has been seen in both rheumatoid joint synovial
fluid and tissue where oxidative products are elevated and
antioxidants are reduced [21–23]. Since weak photon emission is
correlated with oxidation processes, it means that rheumatoid
arthritis might also be studied by photon emission imaging
methods. It was demonstrated that it is feasible to image increased
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ROS levels non-invasively in a RA mouse model using luminol
(intravenously) which, then, acts as a documenter of ROS [24].
Luminol (3-aminophthalic hydrazide) is a small molecule photon
donor which is activated by ROS resulting in more effective
photon emission [25]. However, the effective use of luminol in
human research subjects is highly unlikely. Therefore, a non-
invasive method without the use of an enhancer substance for the
early detection of arthritis development by monitoring ultra-weak
photon emission would undoubtedly be very helpful for both basic
arthritis research and its clinical management of human patients.
The development of such a method would be a challenging
multistep process. Therefore, the aim of such a study would be to
image UPE both without and with the enhancer luminol utilizing
an experimental mouse model for rheumatoid arthritis.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.The
experiments were performed with the approval of the Tohoku
Institute of Technology Research Ethics Committee, Sendai,
Japan (approval date 18 January 2009).
Animals
DBA/1J mice are widely used as an animal model to investigate
rheumatoid arthritis [26,27]. In this model, immunization with
collagen (Type II) will provoke severe polyarthritis by the induced
autoimmune response. Twenty (10 control; 10 experimental) male
DBA/1J mice, 6–7 weeks of age, were utilized in this study. The
mice were obtained from Charles River, Yokohama, Japan. They
were maintained in a temperature and light controlled environ-
ment with free access to standard rodent chow and water.
Induction of Arthritis by Co-administration of Type II
Collagen (CII) with Lipopolysaccharide (LPS)
In experimental animals, RA was induced by co-administration
of type II collagen (CII) with lipopolysaccharide (LPS). One
hundred micrograms of CII extracted from bovine nasal cartilage
(Funakoshi Co., Tokyo, Japan) was dissolved in 100 ml of 0.005 M
acetic acid and injected intraperitoneally (i.p.) into mice (day 0).
Thereafter, the CII injection was repeated i.p. on days 14, 28, 42
and 56. In the control mice, 100 ml of 0.005 M acetic acid alone
was administered i.p. on the same days.
In the experimental mice, 5 mg of LPS from E. coli 011:B4
(Chondrex, Redmond, USA) dissolved in 100 ml phosphate
buffered saline (PBS) was also given i.p. immediately after each
injection of CII. In the control animals, 100 ml PBS was similarly
administered as a control. This protocol for arthritis induction is
extensively described [28].
CCD Camera System
Spectral Instruments 600 series CCD camera system (Spectral
Instruments, Inc., AZ, USA) was used. It has a mounted CCD42-
40 (e2v technologies Ltd., Essex, UK), which was back-illuminated
with a full frame operation CCD with 204862048 pixel resolution
and 13.5613.5 mm pixel size. The camera system is equipped with
a cooling head to maintain the CCD at –120uC utilizing a closed-
cycle mechanical cryogenic unit. Under these conditions, quantum
efficiency is 75% at the peak wavelength. Dark current is 0.65
electron/pixel/h and readout noise in the slow scanning mode is
less than 4.5 electron rms. The CCD camera head had a specially
designed lens system, which was designed to maximize the light
collection efficiency (numerical aperture of the lens system on the
detector side is 0.5 and the number of lenses was restricted to 7
pieces). Magnification of the lens system is ,1/2. In this
experiment, the CCD was operated in the 16616 binning mode.
The actual pixel number was 1286128. Taking into account the
detection limit, which was determined by dark current and
readout noise of the CCD as well as light collection efficiency, the
minimum detectable number of photons on each pixel was
estimated ca 47 photon/s/cm2 on the surface of the subject under
the measurement condition. The CCD camera was mounted on
the top of a dark chamber (Figure 1). The dark chamber was free
from any phosphorescent or synthetic colour. The temperature in
the recording chamber was maintained at 2061.0uC.
Determination of Ultra-weak Photon Emission (UPE)
Ultra-weak photon emission measurement of the front and back
paws of the animals started 70 days after the first injection [28]. All
of the animals were measured once without luminol and once
immediately after luminol injection. Prior to the recording the
animals were anesthetized with isoflurane with the purpose of
keeping animals in exactly the same position during the
measurement. A position image was made under weak light
illumination before the actual imaging of UPE. It was checked that
this weak illumination has no influence on the actual imaging of
UPE. Subsequently, the front area of the animals (focusing on the
front paws) was recorded, immediately followed by the recording
of the back part (focusing on the back paws). The time for each
UPE recording was 15 minutes.
Two days after UPE recording without luminol, the animals
were again recorded for luminol-enhanced luminescence. The
animals were anesthetized and then injected intravenously with
5 mg luminol (3-aminophtalic hydrazide) dissolved in 100 ml PBS.
Recording started immediately thereafter using the above
recording protocol. No adverse effects of the luminol were
observed in mice injected at doses of 250 mg/kg [29].
Data Analysis
Each paw’s image was divided into 5 regions of interests (ROI):
ROI 1 through ROI 5 with ROI 1 closest to the tip of the paw and
ROI 5 closest to the joint of the paw. The other ROI’s were
chosen in such a way that they equally covered the paws between
tip and joint (as marked in the left panel of Figure 2 A and B). The
surface for the ROI’s chosen for the paws was a circle covering 21
pixels (in the case of the front paws) and 32 pixels (in the case of
the hind paws). The off-set level of read-out amplifier is subtracted
from the observed values. In the way described above, photon
emission from each paw can be described by a mean intensity
(counts/15 min/pixel) and standard deviation.
Results
Visual Inspection of CCD Images
CCD imaging started 70 days after RA induction. Visual
inspection of these images documented that in both control and
CII-injected mice, the front paws emitted a higher emission than
the hind paws. In both hind and front paws, the emission after
luminol injection was higher than before the luminol injection.
Figure 2 is a representative example of UPE images registered
from the hind and front paws of a single animal. They suggested a
variation in the intensity between and within the 4 paws of an animal.
This variance in intensity was higher in the experimental animals
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as compared to the control animals. Such variance within an
animal increased after luminol injection. These observations were
quantified according to the protocol described in the data analysis
section.
Quantitative Description of CCD Images
Mean UPE intensity of both experimental (CII injected) and
control group were compared before and after injection of
luminol. Before luminol injection, the average intensities of front
Figure 1. Schematic representation of the experimental set-up.
doi:10.1371/journal.pone.0084579.g001
Figure 2. Image of left and right hind paws (upper panel) and front paws (lower panel) of experimental mouse 7. In both rows, the left
image is a position image, recorded under weak light illumination before the actual imaging of UPE. Middle images represent UPE before luminol
injection. Right images represent UPE immediately after luminol injection.
doi:10.1371/journal.pone.0084579.g002
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and hind paws of individual mice were in the range of 26–80 and
23–61, respectively. In the visual inspection of the images of both
control and CII injected mice it was evident that the emission in
the front paws was higher than in hind paws. For this reason, in
Table 1, UPE intensity of the front and hind paws (for the control
and experimental group) are described separately before luminol
was injected as well as after luminol was injected.
Before luminol injection, the CII-injected mice generally
demonstrated increased emission intensities compared with
control mice. The measured values before luminol injection
documented a significantly higher intensity (p = 0.005) of the front
paws of experimental animals compared to the control animals.
The hind paws had a smaller intensity than the front paws. The
difference between the hind paws of CII injected animals and
controls was smaller and not significant. The photon emission
intensities of all paws of the animal (i.e., the total sum of the
emissions of both left and right, hind and front paws and then
averaged) illustrate a significant higher UPE intensity for the
experimental than for control animals before luminol injection
(p = 0.022).
Table 1, also illustrates the photon emission intensities of the
paws of the CII and control group after luminol injection. The
intensity of the CII group illustrates a significantly higher UPE
intensity than the control group for the front paws (p = 0.001),
hind paws (p = 0,000) and the average of all paws (p = 0.000).
Finally, Table 1 illustrates that luminol increased UPE by a
factor of roughly 2. The increase by luminol injection was
significant for control animals (hind paws p = 0.001; front paws
p = 0.000) and experimental animals (hind paws p = 0.000; front
paws p = 0.000).
The data suggest that the increase in UPE intensity as a result of
the induced arthritis can be significantly observed with, as well as
without luminol.
Correlation between Left and Right
Because UPE was imaged in the early phase of RA develop-
ment, it was of interest to determine the degree of symmetry in
distribution of UPE intensity within an animal. For that reason we
focused on the correlation between intensity values left and right.
Intensity values of left and right (hind and front paws) were
compared for control and CII injected animals before and after
luminol injection.
Figure 3 illustrates different types of comparisons. The upper
panel presents the left and right intensity values of hind and front
paws before luminol injection for the control (Figure 3A) and CII-
injected animals (Figure 3B). The diagram in Figure 3A illustrates
the variance in intensity of control animals ranging from 24–73. In
the experimental group, the values range from 23–145 (Figure 3B).
The broad range is due to the large difference between the UPE
intensities of the front and the hind paws. Therefore, in each panel
the hind and front paws are marked so that they can be
recognized. In the control animals before luminol, the intensities
are relatively low, but small differences between individual animals
have been estimated for both front and hind paws. In the
experimental group (Figure 3B) the values of front and hind paws
are more separated than in the control group (Figure 3A). In both
groups, the correlation between left and right paw intensity was
estimated, both for front and for hind paws. In the control animals
the left-right correlation for the front paws is 0.6434 (p = 0.045)
and for the hind paws 0.4029 (n.s.). In the experimental animals,
the correlation for the front paws is 0.9609 (p = 000) and for the
hind paws 0.7179 (p = 0.019).
The middle row of panels of Figure 3 illustrates left and right
symmetry in intensity after luminol injection. The intensity
between the animals in the control group ranges from 15–124
(Figure 3C). The intensity in the experimental group varies
between 25–436 (Figure 3D). Also, in this case, the left-right
correlation was calculated for front and hind paws separately. In
general, the left-right correlation after luminol was less and only
significant in the hind paws of control animals (r = 0.8467;
p = 0.004).
The lower panels focus on the effect of luminol on UPE
intensity. It compares baseline UPE intensity (before luminol) of
individual animals with the corresponding increased UPE value
after luminol injection of the same animals. The relationship of
UPE intensity within an animal (before and after luminol injection)
is depicted for the control group (Figure 3E) and CII-injected
group (Figure 3F). No significant correlation between intensities
measured before and after luminol were found, neither for the
control group nor for the experimental group.
Discussion
In summary, data illustrate a higher UPE intensity at 70 days
after initiating arthritis by CII- injection of the animals according
to the procedure described [28]. The data confirm the results
demonstrating the increase in UPE in CII-injected animals after
the injection of luminol [24]. The present paper shows that an
increase in UPE in CII-injected animals can also be demonstrated
before using luminol. This indicates that it is feasible to image
increased ROS activity in mice in an early phase of arthritis
development without using luminol as an enhancer.
The present protocol for estimating UPE allows a comparison of
the same animals before and after luminol injection. An interesting
observation is the high variance in UPE intensity between the
animals especially in the animals injected with CII. This high
variance indicates that in some CII-injected animals arthritis is
developed further than in others. The reason is probably because
images were made in the early phase of RA development.
Another interesting observation is the correlation between left
and right paw intensity in the experimental CII animals before
luminol injection (front paws: r = 0.9609; p = 000 and hind paws:
r = 0.7179; p = 0.019). In luminol injected animals the left-right
correlation was less (front paws: r = 0.4649; p = n.s. and hind paws
r = 0.1765; p = n.s.).
The loss of correlation in relationship with the use of luminol
regarding UPE intensity was also observed when UPE before
luminol injection was compared with the corresponding UPE
value after luminol injection. The loss of correlation suggests that
luminol diffusion in tissues is highly variable. Thus, the contribu-
tion of luminol in order to detect RA documents an opposite
trend. On one hand, ROS in the presence of luminol produces
more signal. However, on the other hand, the signal has more
Table 1. Average intensities values and standard deviation of
the 5 ROI’s on front and hind paws for control and CII animals
before and immediately after the injection of luminol.
Before luminol After luminol
Control
animals CII animals p
Control
animals CII animals p
Front 46.469.1 63.4614.0 0.005 81.6614.7 160.1661.1 0.001
Hind 33.366.1 37.566.8 0.162 48.667.3 103.6622.8 0.000
Total 39.8610.1 50.4617.1 0.022 65.1620.4 131.9653.4 0.000
doi:10.1371/journal.pone.0084579.t001
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variation than without luminol. Such may be explained by the
reactivity and distribution of luminol throughout the body. This
needs to be studied and in case this is true, data without luminol
are more reliable (but with less sensitivity).
We envision that the above described technology may be useful
for the future study of human RA. Recently major steps have been
made in the imaging of human ultra-weak photon emission. With
the use of an extremely sensitive CCD camera and lens systems it
is possible to image photon emission from larger human body
surfaces [30–33]. In 2009, the diurnal change of this ultra-weak
photon emission measured from large body surfaces was
demonstrated [34]. Recently, two-dimensional photon imaging
has served as a potential tool for monitoring oxidative stress of
human skin induced by various stress factors [35,36]. Such
examples emphasize the potential applications of UPE imaging
studies within biology, medicine and environmental studies. It
seems likely that this adjunct might rapidly expand in vivo imaging
repertoire. It might be particularly suited for following ROS levels
in real-time and in testing the efficacy of novel therapies.
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corresponding increased UPE value after luminol injection of the same animals. The relationship of UPE intensity within an animal (before and after
luminol injection) for hind (black circles) and front (grey circles) paws is depicted for the control group (Figure 3E) and CII-injected group (Figure 3F).
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